Contact
searchSearch
HMP Global
Login
Guillermo Garcia-Manero, MD
Conference Coverage
Analyzing Management and Treatment Options for Patients With High-Risk MDS
10/08/2024
At the 2024 SOHO meeting, Guillermo Garcia-Manero, MD, shared expert insight into treatment options for patients with high-risk myelodysplastic syndrome.
At the 2024 SOHO meeting, Guillermo Garcia-Manero, MD, shared expert insight into treatment options for patients with high-risk myelodysplastic syndrome.
At the 2024 SOHO meeting,...
10/08/2024
Oncology
Guillermo Garcia-Manero, MD
Conference Coverage
Examining Current and Upcoming Treatment Options for Patients With Low-Risk MDS
10/04/2024
At the 2024 SOHO meeting, Guillermo Garcia-Manero, MD, shared expert insight into treatment options that are available and upcoming for patients with low-risk myelodysplastic syndrome.
At the 2024 SOHO meeting, Guillermo Garcia-Manero, MD, shared expert insight into treatment options that are available and upcoming for patients with low-risk myelodysplastic syndrome.
At the 2024 SOHO meeting,...
10/04/2024
Oncology
Dimopoulos
Conference Coverage
Advancing Treatment Options for High-Risk Multiple Myeloma
10/02/2024
Discover how the addition of daratumumab to standard treatment improves outcomes for patients with high-risk cytogenetic abnormalities in multiple myeloma according to a SOHO 2024 presenter.
Discover how the addition of daratumumab to standard treatment improves outcomes for patients with high-risk cytogenetic abnormalities in multiple myeloma according to a SOHO 2024 presenter.
Discover how the addition of...
10/02/2024
First Report Managed Care
Kerry Rogers, MD
Conference Coverage
Should BTK Inhibitor Treatment be Discontinued Among Patients With CLL?
09/23/2024
At the 2024 SOHO meeting, Kerry Rogers, MD, participated in a debate in which she argued against discontinuing BTK inhibitor treatment among patients with chronic lymphocytic leukemia.
At the 2024 SOHO meeting, Kerry Rogers, MD, participated in a debate in which she argued against discontinuing BTK inhibitor treatment among patients with chronic lymphocytic leukemia.
At the 2024 SOHO meeting, Kerry...
09/23/2024
Oncology
Prithviraj Bose, MD
Conference Coverage
Strategic Treatment Regimens Utilizing Approved JAK Inhibitors for Patients With Myelofibrosis
09/17/2024
At the 2024 SOHO meeting, Prithviraj Bose, MD, discusses currently available JAK inhibitors for the treatment of myelofibrosis, highlighting ruxolitinib, fedratinib, pacritinib, and momelotinib.
At the 2024 SOHO meeting, Prithviraj Bose, MD, discusses currently available JAK inhibitors for the treatment of myelofibrosis, highlighting ruxolitinib, fedratinib, pacritinib, and momelotinib.
At the 2024 SOHO meeting,...
09/17/2024
Oncology
John Mascarenhas, MD
Conference Coverage
Utilizing and Selecting Optimal JAK Inhibitor Therapies for Patients With Myelofibrosis
09/12/2024
At the 2024 SOHO meeting, John Mascarenhas, MD, shares highlights from a discussion on the utilization and selection of optimal JAK inhibitor therapies for the treatment of patients with myelofibrosis.
At the 2024 SOHO meeting, John Mascarenhas, MD, shares highlights from a discussion on the utilization and selection of optimal JAK inhibitor therapies for the treatment of patients with myelofibrosis.
At the 2024 SOHO meeting, John...
09/12/2024
Oncology
John Mascarenhas, MD
Conference Coverage
New and Upcoming Combination and Non-JAK Inhibitor Treatments for Patients With Myelofibrosis
09/12/2024
At the 2024 SOHO meeting, John Mascarenhas, MD reviewed the latest data in myelofibrosis treatment options, including upcoming novel combination and non-JAK inhibitor therapies.
At the 2024 SOHO meeting, John Mascarenhas, MD reviewed the latest data in myelofibrosis treatment options, including upcoming novel combination and non-JAK inhibitor therapies.
At the 2024 SOHO meeting, John...
09/12/2024
Oncology
Marion Subklewe, MD
Conference Coverage
The “ABCs” of Immunotherapy for Patients With Acute Myeloid Leukemia
09/06/2024
At the 2024 SOHO meeting, Marion Subklewe, MD, discusses the current landscape and future development of immune and cellular therapies for patients with acute myeloid leukemia.
At the 2024 SOHO meeting, Marion Subklewe, MD, discusses the current landscape and future development of immune and cellular therapies for patients with acute myeloid leukemia.
At the 2024 SOHO meeting, Marion...
09/06/2024
Oncology
Pinkal Desai, MD
Conference Coverage
Challenges of Treating Secondary Acute Myeloid Leukemia With Standard Therapies
09/05/2024
Pinkal Desai, MD discusses the challenges of existing treatment options for patients with secondary acute myeloid leukemia and the need for further development of therapies for this disease subset.
Pinkal Desai, MD discusses the challenges of existing treatment options for patients with secondary acute myeloid leukemia and the need for further development of therapies for this disease subset.
Pinkal Desai, MD discusses the...
09/05/2024
Oncology
Abdulraheem Yacoub, MD
Conference Coverage
Developments in Utilizing Interferons for the Treatment of Myeloproliferative Neoplasms
09/04/2024
Abdulraheem Yacoub, MD, shares expert insight into the use of interferons for the treatment of patients with myelofibrosis, essential thrombocythemia, and polycythemia vera.
Abdulraheem Yacoub, MD, shares expert insight into the use of interferons for the treatment of patients with myelofibrosis, essential thrombocythemia, and polycythemia vera.
Abdulraheem Yacoub, MD, shares...
09/04/2024
Oncology
Eduardo Rego, MD, PhD
Conference Coverage
Exploring Developments and Challenges of Immunological Approaches in AML Treatment
09/04/2024
At the 2024 Society of Hematologic Oncology meeting, Eduardo Rego, MD, shares his interest in reviewing data on novel research in acute myeloid leukemia treatment development, specifically the incorporation of immunological approaches.
At the 2024 Society of Hematologic Oncology meeting, Eduardo Rego, MD, shares his interest in reviewing data on novel research in acute myeloid leukemia treatment development, specifically the incorporation of immunological approaches.
At the 2024 Society of...
09/04/2024
Oncology
Eduardo Rego, MD, PhD
Conference Coverage
Analyzing Data on the Improvement of International Outcomes of Acute Myeloid Leukemia Therapy
09/04/2024
Eduardo Rego, MD, shares expert insight into International Consortium on Acute Leukemia research on improving the outcomes of therapy for patients with AML treated in Latin America compared to the outcomes of those treated in the US and...
Eduardo Rego, MD, shares expert insight into International Consortium on Acute Leukemia research on improving the outcomes of therapy for patients with AML treated in Latin America compared to the outcomes of those treated in the US and...
Eduardo Rego, MD, shares expert...
09/04/2024
Oncology

The annual Society of Hematologic Oncology (SOHO) Meeting focuses specifically on new advances and practical clinical applications in the field of hematologic malignancies with insights from internationally recognized experts.

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use